Loading data for DNLI — first visit, this takes a few seconds.
Denali Therapeutics Inc. (DNLI)
NasdaqGS: DNLI
· Real-Time Price · USD
24.20
-0.72 (-2.89%)
At close: Aug 24, 2026, 8:00 PM
The price, the headline numbers and the latest news, in one place.
Denali Therapeutics Inc. (DNLI) Stock Price, Analysis & Data
-2.89% (1D)
No data available
| Bid | 17.31 |
| Market Cap | 3.87B |
| Revenue (ttm) | 3.6M |
| Net Income (ttm) | -511.45M |
| 1.00 | |
| -2.76 | |
| n/a | |
| -9.97 | |
| P/B (ttm) | 4.63 |
| P/S (ttm) | 1073.34 |
| Earnings Date | Nov 5, 2026 |
| Ask | 30.42 |
| Volume | 1,321,109 |
| Avg. Volume (20D) | 1,723,309 |
| Open | 24.88 |
| Previous Close | 24.92 |
| Day's Range | 23.41 - 25.27 |
| 52-Week Range | 12.58 - 27.30 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About DNLI
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 8, 2017
Employees 503
Stock Exchange NasdaqGS
Ticker Symbol DNLI
Financial Performance
In 2025, Denali Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -512.54M, an increase of 21.23%.
Financial StatementsEarnings Surprise
Denali Therapeutics has released their quarterly earnings on Aug 6, 2026:
- Revenue of $3.6M misses estimates by $0, with Infinity% YoY growth.
- EPS of -0.68 misses estimates by -0.21, with 5.56% YoY growth.
Denali Therapeutics Inc. is scheduled to release its earnings on Nov 5, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2